Creasallis is a Cambridge based startup looking at re-engineering antibodies to improve their penetration into solid tumours.  It has its own portfolio of solid tumour antibody-based drugs, as well as collaborates with antibody drug developers to improve their existing portfolio.

www.creasallis.com